Sanofi-Aventis

This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (April 2009)

Sanofi-Aventis S.A.

Type	Public (Euronext: SAN, NYSE: SNY, LSE: 0I42, FWB: SNW)
Founded	20 August 2004 (by acquisition)
Headquarters	Paris, France
Key people	Chris Viehbacher (CEO), Jean-François Dehecq (Chairman of the board)
Industry	Pharmaceuticals
Products	Prescription and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines (list...)
Revenue	€27.57 billion (2008)[1]
Operating income	▲ €4.394 billion (2008)[1]
Profit	▲ €3.851 billion (2008)[1]
Employees	98,210 (2008)[1]
Subsidiaries	Sanofi Pasteur
Website	en.sanofi-aventis.com

Sanofi-Aventis (Euronext: SAN, NYSE: SNY), headquartered in Paris, France, is a multinational pharmaceutical company, the world's fourth-largest by prescription sales.^[2][3] Sanofi-Aventis engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Sanofi-Aventis covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).^[4] The company is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).^[5]

Contents 1 History 1.1 Sanofi-Aventis 1.2 Sanofi-Synthélabo 1.3 Aventis 2 Business 2.1 Products 2.2 Management 2.3 Stockholders 3 Collaborative research 4 Aventis Foundation 5 See also 6 References 7 External links

History

Sanofi-Aventis

Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 bn for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 bn in place of the previously rejected hostile bid. French government intervention also played an active role. The French government, desiring what they called a "local solution", put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running.

Sanofi-Synthélabo

Sanofi-Synthélabo was formed in 1999 when Sanofi (former subsidiary of Total) merged with Synthélabo (former subsidiary of L'Oréal). The merged company was based in Paris, France.

Aventis

Aventis was formed in 1999 when Rhône-Poulenc S.A. merged with Hoechst Marion Roussel, which itself was formed from the merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.

Business

Products

Pharmaceuticals produced by Sanofi-Aventis include Lovenox/Clexane for thrombosis (its biggest seller in 2008),^[6] Plavix/Iscover for atherothrombosis, Lantus for diabetes, Taxotere for breast, lung and prostate cancer, Eloxatin for colorectal cancer, Stilnox/Ambien/Ambien CR/Myslee/Zolfresh/Zolt/Stilnoct for insomnia, Copaxone for multiple sclerosis, Aprovel/Avapro/Karvea and Delix/Tritace/Triatec for hypertension, Allegra/Telfast and Nasacort for allergic rhinitis, Menactra for meningitis, Xatral for benign prostatic hyperplasia, Actonel for osteoporosis and Paget’s disease and Depakine and Depakote for epilepsy.

Management

• Jean-François Dehecq, Chairman^[7]
• Chris Viehbacher, CEO^[8]

Dehecq was the General Manager of Sanofi from its creation in 1973 until 2007.

Stockholders

As of 31 January 2009:^[1]

• Breakdown of share ownership: 11.09% by Total, 8.99% by L'Oréal, 0.76% treasury shares and 1.30% employees. The remaining 77.86% are publicly traded.
• Voting rights distribution: 18.11% to Total, 14.89% to L'Oréal, 1.96% to employees, and 65.04% to the public.

Collaborative research

In addition to internal research and development activities Sanofi-Aventis is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.^[9][10] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.^[11]

Aventis Foundation

The Aventis Foundation ^[12], a German charitable trust, was established in 1996 as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. Its aim is to promote music, theater, art, literature, higher education, research (healthcare).

See also

• sanofi-aventis international BioGENEius Challenge
• Sanofi Pasteur

References

External links

• Official site
• Aventis Foundation

v • d • e CAC 40 companies of France Accor · Air France-KLM · Air Liquide · Alcatel-Lucent · Alstom · ArcelorMittal · AXA · BNP Paribas · Bouygues · Capgemini · Carrefour · Crédit Agricole · Dexia · EADS · EDF · Essilor · France Télécom · GDF Suez · Groupe Danone · L'Oréal · Lafarge · Lagardère · LVMH · Michelin · Pernod Ricard · PSA Peugeot Citroën · PPR · Renault · Saint-Gobain · Sanofi-Aventis · Schneider Electric · Société Générale · STMicroelectronics · Suez Environnement · Total · Unibail-Rodamco · Vallourec · Veolia Environnement · VINCI · Vivendi